- (1) Each RMHI shall have a Treatment Review Committee (TRC) to make decisions for patients. A RMHI may have multiple TRCs making decisions in various areas of the facility. If multiple TRCs are established, all must meet the composition requirements of this rule. PSYCHOTROPIC MEDICATIONS AT MENTAL HEALTH INSTITUTES
(2) The Chief Executive Officer or designee shall appoint the Treatment Review Committee members. A TRC shall be composed of four or more members. The members shall be:
(a) A chair, designated by the Chief Executive Officer or designee, who shall be responsible for conducting the TRC meeting in accordance with these rules and for assuring that all required TRC documentation is completed as required by these rules. One of the following shall be designated as the chair of the TRC:
- 1. For TRCs considering psychotropic medication, the chair shall be a member of the RMHI Clinical Staff.
- 2. For TRCs considering physical treatment, the chair shall be a member of the RMHI Medical Staff.
- 3. For TRCs considering release of information, the chair shall be a member of the RMHI Medical Staff or a qualified mental health professional.
- (b) The Patient Rights Advocate, and
- (c) Two (2) or more of the following: a physician, an advanced practice nurse, a physician assistant, a pharmacist, a registered nurse, a psychologist with health service provider designation, a psychological examiner or senior psychological examiner with health service provider designation, a master’s level social worker, a professional counselor, a marital and family therapist, or a clinical chaplain.
- (3) No person who is a member of a patient’s Treatment Team shall serve on a TRC for that patient.
- (4) A TRC that considers psychotropic medication shall include a psychiatrist, a psychiatric advanced practice nurse, or a psychiatric physician assistant.
- (5) A TRC that considers physical treatment, including medication, for a physical condition or illness shall include a physician, an advanced practice nurse, or a physician assistant.
- (6) The TRC shall encourage the patient to participate in the TRC meeting to the extent possible.
- (7) The patient’s family members, support persons, conservator, or other legal representative may attend the TRC meeting.
- (8) At the discretion of the TRC, members of the patient’s treatment team may be requested to attend the TRC meeting to provide input.
- (9) Unless clinically contraindicated, a TRC meeting may be held by phone, video-conference, or other electronic means that allows full participation by the patient, all members of the TRC, and the patient’s conservator or other legal representative, if applicable. If the TRC meeting is conducted in this manner, at least one (1) member of the TRC shall be physically present with the patient.
- (10) If the patient requests a review by the TRC, the PRA shall immediately request a review by the TRC, unless the TRC has met on the same issue for the patient during the two (2) weeks prior to the request during the same admission.
- (11) The patient may request the PRA or another staff member, including a member of the patient’s treatment team, to assist or to speak on the patient’s behalf in all TRC meetings.
Authority: T.C.A. §§ 33-1-302 through 33-1-305, 33-3-104, 33-6-107, and 33-6-1006. Administrative History: New rules filed December 22, 2025; effective March 22, 2026.